In addition to its prognostic value, loss of SMAD4 expression has been shown to be associated with worse response to fluorouracil-based treatment in colorectal cancer (13) and to concurrent chemotherapy along with local control treatment in a subset of patients with pancreatic cancer with locoregional recurrences (18). This evidence concerns the gene SMAD4 and pancreatic neoplasm.